Company news

Spero Therapeutics, Inc. news in 2024

Spero Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update

November 13, 2024

Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update

October 28, 2024

Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024

October 15, 2024

Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy

October 1, 2024

Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update

August 4, 2024

Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update

May 14, 2024

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 30, 2024

Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update

March 12, 2024

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024

March 5, 2024

Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections

February 27, 2024

Spero Therapeutics Provides Corporate Update and 2024 Outlook

January 4, 2024

Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

January 1, 2024

Calls in 2024

Decks in 2024